PT Jayamas Medica Industri Tbk (ISX:OMED) Debt-to-EBITDA : 0.49 (As of Mar. 2024)

View and export this data going back to 2022. Start your Free Trial

What is PT Jayamas Medica Industri Tbk Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

PT Jayamas Medica Industri Tbk's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was Rp3,498 Mil. PT Jayamas Medica Industri Tbk's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was Rp176,008 Mil. PT Jayamas Medica Industri Tbk's annualized EBITDA for the quarter that ended in Mar. 2024 was Rp365,238 Mil. PT Jayamas Medica Industri Tbk's annualized Debt-to-EBITDA for the quarter that ended in Mar. 2024 was 0.49.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for PT Jayamas Medica Industri Tbk's Debt-to-EBITDA or its related term are showing as below:

ISX:OMED' s Debt-to-EBITDA Range Over the Past 10 Years
Min: 0.01 Med: 0.24 Max: 0.51
Current: 0.47

During the past 5 years, the highest Debt-to-EBITDA Ratio of PT Jayamas Medica Industri Tbk was 0.51. The lowest was 0.01. And the median was 0.24.

ISX:OMED's Debt-to-EBITDA is ranked better than
69.63% of 438 companies
in the Medical Devices & Instruments industry
Industry Median: 1.255 vs ISX:OMED: 0.47

PT Jayamas Medica Industri Tbk Debt-to-EBITDA Historical Data

The historical data trend for PT Jayamas Medica Industri Tbk's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

PT Jayamas Medica Industri Tbk Debt-to-EBITDA Chart

PT Jayamas Medica Industri Tbk Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-EBITDA

0.01

0.19

0.24

0.48

0.51

PT Jayamas Medica Industri Tbk Quarterly Data
	Dec19	Dec20	Mar21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Debt-to-EBITDA	Get a 7-Day Free Trial								0.63	0.61	0.51	0.41	0.49

Competitive Comparison of PT Jayamas Medica Industri Tbk's Debt-to-EBITDA

For the Medical Instruments & Supplies subindustry, PT Jayamas Medica Industri Tbk's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

PT Jayamas Medica Industri Tbk's Debt-to-EBITDA Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, PT Jayamas Medica Industri Tbk's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where PT Jayamas Medica Industri Tbk's Debt-to-EBITDA falls into.

PT Jayamas Medica Industri Tbk Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

PT Jayamas Medica Industri Tbk's Debt-to-EBITDA for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-EBITDA	=	Total Debt			/	EBITDA
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	EBITDA
	=	(13621.173	+	175606.794)	/	371384.484
	=	0.51

PT Jayamas Medica Industri Tbk's annualized Debt-to-EBITDA for the quarter that ended in Mar. 2024 is calculated as

Debt-to-EBITDA	=	Total Debt			/	EBITDA
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	EBITDA
	=	(3497.79	+	176007.704)	/	365238
	=	0.49

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Mar. 2024) EBITDA data.

PT Jayamas Medica Industri Tbk (ISX:OMED) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.

Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

PT Jayamas Medica Industri Tbk Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of PT Jayamas Medica Industri Tbk's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.

PT Jayamas Medica Industri Tbk (ISX:OMED) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » PT Jayamas Medica Industri Tbk (ISX:OMED) » Definitions » Debt-to-EBITDA

Comparable Companies

Traded in Other Exchanges

N/A

Address

Sebelah Selatan Jalan By Pass RT 05 / RW 01, Kelurahan Sidomojo, Kecamatan Krian, Sidoarjo, Jawa Timur, East Java, IDN, 61262

Website

https://www.onemed.co.id

PT Jayamas Medica Industri Tbk is engaged in the business of manufacturing medical devices and other household health supplies. It initially began with the manufacture of urine bags, OneMed later expanded in the manufacturing business of medical equipment and supplies in Indonesia with a range of variants of products manufactured locally. The Company and its Subsidiaries has three main divisions: Manufacturing; Distribution and Retail.